Comparison of Injectable and Advanced Platelet-Rich Fibrin with Bone Graft in the Treatment of Bone Defects in Patients with Chronic Gum Disease

Comparative Clinical and Radiographic Evaluation of Autologous Injectable Platelet Rich Fibrin (I-PRF +) with Nanocrystalline Hydroxyapatite and Beta tricalcium phosphate composite alloplastic graft (Sybograf Plus) and Autologous Advanced Platelet Rich Fibrin (A-PRF +) with Nanocrystalline Hydroxyapatite and Beta tricalcium phosphate composite alloplastic graft (Sybograf Plus) in the Treatment of Intrabony Defects in Chronic Periodontitis Patients A Randomized Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112117

Enrollment

Registered

2026-06-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Injectable Platelet Rich Fibrin and Nanocrystalline Hydroxyapatite and Beta tricalcium phosphate graft: Autologous Injectable Platelet Rich Fibrin (I-PRF +) in combination with Nanocrys

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients in the age group between 25-60 yrs. 2) Patients diagnosed with Chronic Periodontitis. 3) Patients who are non-smokers or do not consume tobacco in any other form. 4) Patients are in good systemic health with no contraindication to periodontal surgery. 5) Patients having pocket depths greater than 5mm, intraosseous defects greater than 3mm and with radiographic evidence of vertical / angular bone loss in the affected sites.

Exclusion criteria

Exclusion criteria: 1) One-walled osseous defects. 2) Patients suffering from any systemic diseases or with a compromised immune system. 3) Patients who had received any type of periodontal therapy for the past 6 months. 4) Patients taking immunosuppressant drugs like corticosteroids. 5) Patients with a known history of allergy to Doxycycline or Chlorhexidine or any other medicine used in the study. 6) Patients showing unacceptable oral hygiene compliance during / after Phase I periodontal therapy. 7) Patients taking any drug known to cause gingival enlargement. 8) Pregnant and/or lactating mothers.

Design outcomes

Primary

Measure	Time frame
1. Plaque Index (P.I.) (Tureskey-Gilmore-Glickman Modification of Quigley Hein) 2. Gingival Index (G.I.) (Loe and Silness, 1963) 3. Probing Pocket Depth (PPD) 4. Clinical Attachment Level (CAL)Timepoint: 1)At Baseline 2)After 1 month 3)After 3 month 4)After 6 month	—

Secondary

Measure	Time frame
The radiographic bone fill will be evaluated using Intraoral Periapical Radiographs of the surgical site.Timepoint: 1)At Baseline 2)After 1 month 3)After 3 month 4)After 6 month	—

Countries

India

Contacts

Public ContactDr Mala Dixit Baburaj

Nair Hospital Dental College ,Mumbai

maladixit25@gmail.com9223340938

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026